个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3rd Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 中华系列

作者：
Xu, Yang[1,2] * ; Wu, Xiao-Ning[1,2] ; Shi, Yi-Wen[1,2] ; Wei, Wei[3] ; Yang, Ai-Ting[1,2] ; Sun, Ya-Meng[1,2] ; Zhao, Wen-Shan[1,2] ; You, Hong[1,2] ;
单位： [1]Capital Med Univ, Dept Liver Res Ctr, Beijing Friendship Hosp, Beijing Key Lab Translat Med Liver Cirrhosis, Beijing 100050, Peoples R China [2]Natl Clin Res Ctr Digest Dis, Beijing 100050, Peoples R China [3]Capital Med Univ, Beijing Friendship Hosp, Clin Epidemiol & Evidence Based Med Ctr, Beijing 100050, Peoples R China
出处：
DOI： 10.4103/0366-6999.160488
ISSN：

关键词： Area Under Receiver Operating Characteristic Curve Baseline Parameters Cirrhosis Entecavir Hepatitis B viral

摘要：
Background: Cirrhosis is a common complication of chronic hepatitis B. It remains unclear if viral and biochemical parameters at baseline affect virological response to entecavir and therefore warrant investigation. In the present study, we aimed to evaluate the efficacy of entecavir therapy by monitoring virological response at the end of the 3rd month of treatment and try to figure out whether baseline factors could help predict it in a cohort of hepatitis B virus (HBV) compensated cirrhosis patients and to determine the cut-off value of a predicting parameter. Methods: A total of 91 nucleos(t)ide-nave patients with HBV induced cirrhosis (compensatory stage) were enrolled in a prospective cohort. HBV DNA and alanine aminotransferase (ALT) were tested at baseline and monitored every 3-6 months after starting therapy. Results: Of all 91 patients, the median follow-up time was 12 (9-24) months. Overall, 64 patients (70.3%) achieved virological response in the 3rd month. Univariate analysis showed that the 3rd month virological response can be predicted by baseline HBV DNA levels (P < 0.001, odds ratio [OR]: 2.13, 95% confidence interval [CI]: 1.44-3.15), ALT value (P = 0.023, OR: 1.01, 95% CI: 1.00-1.01) and hepatitis B e antigen (HBeAg) negativity (P = 0.016, OR: 0.30, 95% CI: 0.11-0.80). Multiple regression analysis showed baseline HBV DNA level was the only parameter related to full virological response. Higher baseline HBV DNA strata indicated a higher probability that HBV DNA remains detectable at the 3rd month (P = 0.001). Area under receiver operating characteristic curve for determining the 3rd month virological response by baseline HBV DNA was 77.6% (95% CI: 66.7-85.2%), with a best cut-off value of 5.8 log(10) . Conclusions: Baseline HBV DNA, HBeAg negativity, and ALT were independent factors contributing to virological response at the 3rd month. Further, multiple regression showed that HBV DNA level was the only parameter predicting full virological response as early as the 3rd month, in this cirrhosis cohort.

基金：
Key Project from Beijing Municipal Science and Technology Commission [D121100003912003]; Program of National Science and Technology Major Project [2013ZX10002004]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX201308]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类 | 4 区 医学
小类 | 4 区 医学：内科
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：内科
JCR分区：
出版当年[2013]版：
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 最新[2023版] 最新五年平均[2021-2025] 出版当年[2013版] 出版当年五年平均[2009-2013] 出版前一年[2012版] 出版后一年[2014版]

第一作者：
第一作者单位： [1]Capital Med Univ, Dept Liver Res Ctr, Beijing Friendship Hosp, Beijing Key Lab Translat Med Liver Cirrhosis, Beijing 100050, Peoples R China [2]Natl Clin Res Ctr Digest Dis, Beijing 100050, Peoples R China
通讯作者：
通讯机构： [1]Capital Med Univ, Dept Liver Res Ctr, Beijing Friendship Hosp, Beijing Key Lab Translat Med Liver Cirrhosis, Beijing 100050, Peoples R China [2]Natl Clin Res Ctr Digest Dis, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714)：
Xu Yang,Wu Xiao-Ning,Shi Yi-Wen,et al.Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3rd Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis[J].CHINESE MEDICAL JOURNAL.2015,128(14):1867-1872.doi:10.4103/0366-6999.160488.
APA：
Xu, Yang,Wu, Xiao-Ning,Shi, Yi-Wen,Wei, Wei,Yang, Ai-Ting...&You, Hong.(2015).Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3rd Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.CHINESE MEDICAL JOURNAL,128,(14)
MLA：
Xu, Yang,et al."Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3rd Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis".CHINESE MEDICAL JOURNAL 128..14(2015):1867-1872

相关文献

[1]Immunological approaches to the breakdown of hepatitis B viral persistence [2]Entecavir results in a rapid reduction in viral load in chronic hepatitis B patients who have failed lamivudine therapy: a randomized, placebo-controlled study in China [3]慢性乙型肝炎及其相关肝硬化抗病毒治疗:单药还是联合? [4]Vitamin D serum level is associated with Child-Pugh score and metabolic enzyme imbalances, but not viral load in chronic hepatitis B patients [5]Entecavir results in early viral load reduction in chronic hepatitis B patients who have failed lamivudine therapy: A randomized, placebo-controlled study in China [6]Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up [7]Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound [8]TRACE HBV REMAINS CAPABLE OF INDUCING FIBROSIS PROGRESSION AFTER ANTI-VIRAL TREATMENT IN CHRONIC HEPATITIS B PATIENTS [9]Entecavir (ETV) results in early viral load reduction in chronic hepatitis B (CHB) patients who have failed lamivudine (LVD) therapy: a randomized, placebo-controlled study in China (study ETV-056) [10]Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC)

资源点击量：1320 今日访问量：0 总访问量：816 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）